First-line dual immune checkpoint inhibitor therapies versus combination therapies comprising immune checkpoint inhibitors and tyrosine kinase inhibitors for advanced renal cell carcinoma: a comparative analysis of the effectiveness using real-world data.
Hiroki IshiharaKenji OmaeYuki NemotoRyo IshiyamaHidekazu TachibanaKoichi NishimuraTakashi IkedaYuki KobariHironori FukudaKazuhiko YoshidaHiroaki ShimmuraYasunobu HashimotoJunpei IizukaTsunenori KondoToshio TakagiPublished in: International journal of clinical oncology (2024)
IO-TKI therapy exhibited superior effectiveness over IO-IO therapy in terms of PFS improvement and immediate disease progression prevention and was associated with a higher risk of treatment interruption and a lower risk of needing corticosteroids.